These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 36041707)

  • 1. Population pharmacokinetics of posaconazole in Chinese pediatric patients with acute leukaemia: Effect of food on bioavailability and dose optimization.
    Lin D; Yu L; Shang D; Huang L; Wu L; Liao X; Zhang Y; Zi J; Zhang J; Zeng Y; Wang X; Yang L
    Eur J Pharm Sci; 2022 Nov; 178():106289. PubMed ID: 36041707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Population Pharmacokinetic Modeling and Simulation Study of Posaconazole Oral Suspension in Immunocompromised Pediatric Patients: A Short Communication.
    Elkayal O; Spriet I; Uyttebroeck A; Colita A; Annaert P; Allegaert K; Smits A; Van Daele R; Dreesen E
    Ther Drug Monit; 2021 Aug; 43(4):512-518. PubMed ID: 33560094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population Pharmacokinetics of Posaconazole Tablets and Monte Carlo Simulations To Determine whether All Patients Should Receive the Same Dose.
    Petitcollin A; Boglione-Kerrien C; Tron C; Nimubona S; Lalanne S; Lemaitre F; Bellissant E; Verdier MC
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Model Based Estimation of Posaconazole Tablet and Suspension Bioavailability in Hospitalized Children Using Real-World Therapeutic Drug Monitoring Data in Patients Receiving Intravenous and Oral Dosing.
    Kane Z; Cheng I; McGarrity O; Chiesa R; Klein N; Cortina-Borja M; Standing JF; Gastine S
    Antimicrob Agents Chemother; 2023 Jul; 67(7):e0007723. PubMed ID: 37260401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Integrated Population Pharmacokinetic Analysis for Posaconazole Oral Suspension, Delayed-Release Tablet, and Intravenous Infusion in Healthy Volunteers.
    Chen L; Krekels EHJ; Heijnen AR; Knibbe CAJ; Brüggemann RJ
    Drugs; 2023 Jan; 83(1):75-86. PubMed ID: 36607589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and Safety of Posaconazole Administered by Intravenous Solution and Oral Tablet in Healthy Chinese Subjects and Effect of Food on Tablet Bioavailability.
    Li H; Wei Y; Zhang S; Xu L; Jiang J; Qiu Y; Mangin E; Zhao XM; Xie S
    Clin Drug Investig; 2019 Nov; 39(11):1109-1116. PubMed ID: 31432392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of Posaconazole Oral Suspension in Children Dosed According to Body Surface Area.
    Vanstraelen K; Colita A; Bica AM; Mols R; Augustijns P; Peersman N; Vermeersch P; Annaert P; Spriet I
    Pediatr Infect Dis J; 2016 Feb; 35(2):183-8. PubMed ID: 26544987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A population pharmacokinetic model for posaconazole intravenous solution and oral powder for suspension formulations in pediatric patients with neutropenia.
    Winchell G; de Greef R; Ouerdani A; Fauchet F; Wrishko RE; Mangin E; Bruno C; Waskin H
    Antimicrob Agents Chemother; 2024 Apr; 68(4):e0119723. PubMed ID: 38376229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection.
    Cornely OA; Helfgott D; Langston A; Heinz W; Vehreschild JJ; Vehreschild MJ; Krishna G; Ma L; Huyck S; McCarthy MC
    Antimicrob Agents Chemother; 2012 May; 56(5):2652-8. PubMed ID: 22290953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of patient education on plasma concentrations and effectiveness of posaconazole oral suspension under clinical conditions.
    Geist MJP; Egerer G; Mikus G; Blank A; Hohmann N; Heinz WJ; Carls A
    Basic Clin Pharmacol Toxicol; 2019 Jan; 124(1):56-61. PubMed ID: 29989301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome.
    Vehreschild JJ; Müller C; Farowski F; Vehreschild MJ; Cornely OA; Fuhr U; Kreuzer KA; Hallek M; Kohl V
    Eur J Clin Pharmacol; 2012 Jun; 68(6):987-95. PubMed ID: 22286158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.
    Krishna G; AbuTarif M; Xuan F; Martinho M; Angulo D; Cornely OA
    Pharmacotherapy; 2008 Oct; 28(10):1223-32. PubMed ID: 18823218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid concentrations of posaconazole in paediatric leukaemia patients.
    Körholz K; Holterhus M; Gordon K; Müller-Ohrem C; Müller C; Groll AH
    J Antimicrob Chemother; 2024 Mar; 79(3):564-566. PubMed ID: 38198576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and Safety of Posaconazole Tablet Formulation in Chinese Participants at High Risk for Invasive Fungal Infection.
    Liu K; Wu D; Li J; Chen H; Ning H; Zhao T; Dai H; Chen L; Mangin E; Winchell GA; Waskin H; Jiang J; Qiu Y; Zhao XM
    Adv Ther; 2020 May; 37(5):2493-2506. PubMed ID: 32319040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Drug Monitoring and Dose Adjustment of Posaconazole Oral Suspension in Adults With Acute Myeloid Leukemia.
    Hummert SE; Green MR
    Ther Drug Monit; 2015 Aug; 37(4):508-11. PubMed ID: 25549205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Population Pharmacokinetic Model for a Solid Oral Tablet Formulation of Posaconazole.
    van Iersel MLPS; Rossenu S; de Greef R; Waskin H
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29712663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective analysis of goal drug level attainment of posaconazole for invasive fungal infection prophylaxis in patients with acute myeloid leukemia pre- and post-switch to tablet formulation.
    Liebenstein TK; Widmer KM; Fallon MJ
    J Oncol Pharm Pract; 2018 Dec; 24(8):599-603. PubMed ID: 28768441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Posaconazole bioavailability of the solid oral tablet is reduced during severe intestinal mucositis.
    Jansen AME; Muilwijk EW; van der Velden WJFM; Maertens JA; Aerts R; Colbers A; Burger D; Verweij PE; Ter Heine R; Blijlevens NMA; Brüggemann RJM
    Clin Microbiol Infect; 2022 Jul; 28(7):1003-1009. PubMed ID: 35150880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Pharmacokinetics and Dose Recommendations for Posaconazole in Infants and Children.
    Boonsathorn S; Cheng I; Kloprogge F; Alonso C; Lee C; Doncheva B; Booth J; Chiesa R; Irwin A; Standing JF
    Clin Pharmacokinet; 2019 Jan; 58(1):53-61. PubMed ID: 29679234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults.
    Courtney R; Wexler D; Radwanski E; Lim J; Laughlin M
    Br J Clin Pharmacol; 2004 Feb; 57(2):218-22. PubMed ID: 14748822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.